度伐利尤单抗联合卡铂/紫杉醇序贯度伐利尤单抗维持治疗联合或不联合奥拉帕利一线治疗晚期子宫内膜癌:III期DUO-E试验
这项III期全球双盲安慰剂对照试验将718例新诊断晚期或复发性子宫内膜癌患者按1:1:1随机分入对照组、度伐利尤单抗组和度伐利尤单抗+奥拉帕利组。在意向治疗人群中,度伐利尤单抗组和度伐利尤单抗+奥拉帕利组对比对照组均显示统计学显著的PFS获益。
要点
- 度伐利尤单抗组对比对照组PFS的HR为0.71(95%CI 0.57-0.89;P=.003)。
- 度伐利尤单抗+奥拉帕利组对比对照组PFS的HR为0.55(95%CI 0.43-0.69;P<.0001)。
- dMMR和pMMR亚组均观察到PFS获益,安全性特征与单药基本一致。
核心结论
- 卡铂/紫杉醇联合度伐利尤单抗序贯度伐利尤单抗维持治疗联合或不联合奥拉帕利,在晚期或复发性子宫内膜癌患者中显示出统计学显著且具有临床意义的PFS获益。
研究设计与样本
- 这项III期、全球、双盲、安慰剂对照试验将符合条件的初诊晚期或复发性子宫内膜癌患者按1:1:1随机分组。
- 对照组:卡铂/紫杉醇+度伐利尤单抗安慰剂,序贯安慰剂维持治疗。
- 度伐利尤单抗组:卡铂/紫杉醇+度伐利尤单抗,序贯度伐利尤单抗+奥拉帕利安慰剂维持治疗。
- 度伐利尤单抗+奥拉帕利组:卡铂/紫杉醇+度伐利尤单抗,序贯度伐利尤单抗+奥拉帕利维持治疗。
- 共718例患者被随机分配;主要终点为度伐利尤单抗组对比对照组和度伐利尤单抗+奥拉帕利组对比对照组的PFS。
主要发现
- 在意向治疗人群中,度伐利尤单抗组对比对照组PFS的HR为0.71(95%CI 0.57-0.89;P=.003)。
- 度伐利尤单抗+奥拉帕利组对比对照组PFS的HR为0.55(95%CI 0.43-0.69;P<.0001)。
- 预设探索性亚组分析显示dMMR亚组PFS获益:度伐利尤单抗组对比对照组HR为0.42(95%CI 0.22-0.80),度伐利尤单抗+奥拉帕利组对比对照组HR为0.41(95%CI 0.21-0.75)。
- pMMR亚组PFS获益:度伐利尤单抗组对比对照组HR为0.77(95%CI 0.60-0.97),度伐利尤单抗+奥拉帕利组对比对照组HR为0.57(95%CI 0.44-0.73)。
- PD-L1阳性亚组PFS获益:度伐利尤单抗组对比对照组HR为0.63(95%CI 0.48-0.83),度伐利尤单抗+奥拉帕利组对比对照组HR为0.42(95%CI 0.31-0.57)。
关键数值与推荐
- 中期总生存结果(成熟度约28%)支持主要结局:度伐利尤单抗组对比对照组HR为0.77(95%CI 0.56-1.07;P=.120),度伐利尤单抗+奥拉帕利组对比对照组HR为0.59(95%CI 0.42-0.83;P=.003)。
- 试验组的安全性特征与各单药基本一致。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Immunotherapy and chemotherapy combinations have shown activity in endometrial cancer, with greater benefit in mismatch repair (MMR)-deficient (dMMR) than MMR-proficient (pMMR) disease. Adding a poly(ADP-ribose) polymerase inhibitor may improve outcomes, especially in pMMR disease. METHODS: This phase III, global, double-blind, placebo-controlled trial randomly assigned eligible patients with newly diagnosed advanced or recurrent endometrial cancer 1:1:1 to: carboplatin/paclitaxel plus durvalumab placebo followed by placebo maintenance (control arm); carboplatin/paclitaxel plus durvalumab followed by maintenance durvalumab plus olaparib placebo (durvalumab arm); or carboplatin/paclitaxel plus durvalumab followed by maintenance durvalumab plus olaparib (durvalumab + olaparib arm). The primary end points were progression-free survival (PFS) in the durvalumab arm versus control and the durvalumab + olaparib arm versus control. RESULTS: Seven hundred eighteen patients were randomly assigned. In the intention-to-treat population, statistically significant PFS benefit was observed in the durvalumab (hazard ratio [HR], 0.71 [95% CI, 0.57 to 0.89]; P = .003) and durvalumab + olaparib arms (HR, 0.55 [95% CI, 0.43 to 0.69]; P < .0001) versus control. Prespecified, exploratory subgroup analyses showed PFS benefit in dMMR (HR [durvalumab v control], 0.42 [95% CI, 0.22 to 0.80]; HR [durvalumab + olaparib v control], 0.41 [95% CI, 0.21 to 0.75]) and pMMR subgroups (HR [durvalumab v control], 0.77 [95% CI, 0.60 to 0.97]; HR [durvalumab + olaparib v control] 0.57; [95% CI, 0.44 to 0.73]); and in PD-L1-positive subgroups (HR [durvalumab v control], 0.63 [95% CI, 0.48 to 0.83]; HR [durvalumab + olaparib v control], 0.42 [95% CI, 0.31 to 0.57]). Interim overall survival results (maturity approximately 28%) were supportive of the primary outcomes (durvalumab v control: HR, 0.77 [95% CI, 0.56 to 1.07]; P = .120; durvalumab + olaparib v control: HR, 0.59 [95% CI, 0.42 to 0.83]; P = .003). The safety profiles of the experimental arms were generally consistent with individual agents. CONCLUSION: Carboplatin/paclitaxel plus durvalumab followed by maintenance durvalumab with or without olaparib demonstrated a statistically significant and clinically meaningful PFS benefit in patients with advanced or recurrent endometrial cancer.
引用
- Westin SN, Moore K, Chon HS, et al. Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial. J Clin Oncol. 2023. PMID: 37864337. doi:10.1200/JCO.23.02132
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。